Peptide Comparison
Liraglutide vs Orforglipron
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Liraglutide and Orforglipron share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Liraglutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Liraglutide's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Liraglutide | Orforglipron | |
|---|---|---|
| Class | GLP-1 receptor agonist | Oral non-peptide GLP-1 agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | GLP-1R agonist; albumin-binding fatty acid extends half-life | Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment [14] |
| Route | SC injection | Oral |
| Half-life | ~13 hrs | ~29-49 hrs |
| Dosage (research) | 0.6 mg SC daily (Victoza/Saxenda label starting dose, escalate weekly by 0.6 mg to 1.8 mg/day for T2D per Victoza or 3 mg/day for obesity per Saxenda label) | 0.8 mg orally once daily (FOUNDAYO label starting dose, escalate at intervals of at least 30 days through 2.5, 5.5, 9 and 14.5 mg to label max 17.2 mg once daily) [15] |
| Evidence tier | FDA-Approved | FDA-Approved |
| Research depth | 321 indexed | 197 indexed |
| Availability | Prescription | Prescription |
| Reported risks | Nausea; vomiting; pancreatitis; gallbladder disease; thyroid C-cell tumor warning | GI effects; hepatic enzyme elevations |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Liraglutide or Orforglipron?
Liraglutide and Orforglipron share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Liraglutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Liraglutide's evidence base is currently denser.
What is the difference between Liraglutide and Orforglipron?
Liraglutide is classed as GLP-1 receptor agonist; Orforglipron is classed as Oral non-peptide GLP-1 agonist. Reported mechanism: Liraglutide, GLP-1R agonist; albumin-binding fatty acid extends half-life; Orforglipron, Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment. Reported half-life: Liraglutide, ~13 hrs; Orforglipron, ~29-49 hrs. Routes in published studies: Liraglutide, SC injection; Orforglipron, Oral.
Which has stronger evidence, Liraglutide or Orforglipron?
Liraglutide and Orforglipron sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Liraglutide is graded FDA-Approved, with 64 cited sources on its reference page and 321 indexed studies. Orforglipron is graded FDA-Approved, with 38 cited sources on its reference page and 197 indexed studies.
Which is more accessible, Liraglutide or Orforglipron?
Both Liraglutide and Orforglipron are FDA-approved drugs. Catalog status: Liraglutide, Prescription; Orforglipron, Prescription.
Are Liraglutide and Orforglipron ever combined?
Liraglutide and Orforglipron appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…